Page 634«..1020..633634635636..640650..»

Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine – KALB News

Posted: October 16, 2021 at 2:19 am

- Collaboration to Leverage Omega Epigenomic Controllers, a New Class of mRNA Therapeutics as Programmable Epigenetic Medicines, for Ocular Diseases by Targeting and Controlling Specific Ocular Disease Genes

Published: Oct. 14, 2021 at 6:00 AM CDT

CAMBRIDGE, Mass., Oct. 14, 2021 /PRNewswire/ --Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues.

Under the terms of the collaboration, Omega and members of the Ophthalmology Department of Stanford University School of Medicine will use the OMEGA Epigenomic Programming platform to discover and research novel ocular targets for potential futureOEC development candidates. Albert Wu, M.D., Ph.D., FACS, Associate Professor of Ophthalmology, will serve as principal investigator. Other contributors will include Jeffrey Goldberg, M.D., Ph.D., Professor and Chair of Ophthalmology, and Michael Kapiloff, M.D., Ph.D., Associate Professor (Research) of Ophthalmology.

"Through this research collaboration, we aim to expand the reach of our OMEGA platform within regenerative medicine, immunology, and inflammation with ocular disease targets," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "We will continue exploration of the broad potential of our disruptive platform and OECs, our new class of mRNA therapeutics as programmable epigenetic medicines."

Detailed financial terms of the collaboration were not disclosed.

About Omega Therapeutics

Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming platform. The OMEGA platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visitomegatherapeutics.com, or follow us onTwitterandLinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations for the collaboration with Stanford and our OMEGA Epigenomic ProgramingTMplatform.These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights.These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form10-Q for the period ended June 30, 2021and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Investor contact: Kevin Murphy/Brendan BurnsArgot Partners 212.600.1902 ArgotOmega@argotpartners.com

Media contact: David Rosen Argot Partners 212.600.1902 david.rosen@argotpartners.com

View original content to download multimedia:

SOURCE Omega Therapeutics

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Continue reading here:
Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine - KALB News

Posted in Regenerative Medicine | Comments Off on Omega Therapeutics Announces Strategic Research Collaboration with Stanford University School of Medicine – KALB News

Amniotic Products Market: Growing incidence of burn injuries to drive the market – BioSpace

Posted: October 16, 2021 at 2:19 am

Amniotic Products Market: Overview

The amniotic products market is estimated to observe considerable growth during the forecast period of 2021-2031. The growing incidence of burn injuries among a considerable chunk of the global populace coupled with an increase in the awareness programs will assure steady growth for the amniotic products market.

The growing number of traumatic wounds and the rise in ophthalmology, orthopedic, and cosmetic surgeries will have a profound impact on the growth of the amniotic products market. Amniotic-derived products are a subtype of orthobiologic, examined as a latent treatment option through amplification of joint inflammation and healing. The heightening use of these products in several healing applications will present a plethora of growth opportunities for the global market.

Read Report Overview - https://www.transparencymarketresearch.com/amniotic-products-market.html

The use of amniotic products has evolved considerably over the years. The growing use of amniotic membranes for a plethora of conditions related to ophthalmology such as retinal detachments, corneal surface lesions, and limbal stem cell generation will invite exponential growth for the amniotic products market. Furthermore, the research into amniotic products has increased extensively over the years, especially across orthopedics. Hence, these factors will have a profound impact on the growth of the amniotic products market.

Transparency Market Research (TMR) has obtained considerable information on the overall growth trajectory of the amniotic products market. The upcoming report on the amniotic products market gives a detailed insight about diverse growth aspects. Furthermore, the COVID-19 impact is also included in the report.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_83262

TMR W.I.N Approach

TheW.I.N(Wholesome Competitive Insights.Important Trends.Noteworthy Regions.) Approach makes TMR one of the best research companies in the industry. This approach assures on-point information to the stakeholders and the CXOs.

Amniotic Products Market: Wholesome Competitive Insights

The amniotic products market has numerous players. The players formulate numerous strategies and methods to increase their consumer base. Research and development activities are one of them. The players invest in these activities for accelerating developments and finding insights. All these activities eventually add value to the growth trajectory of the amniotic products market.

Strategic collaborations are of immense importance for the amniotic products market. Mergers, acquisitions, joint ventures, and partnerships help in strengthening the influence of the players in the amniotic products market. All these aspects ultimately contribute to the growth of the amniotic products market.

Some well-established players in the amniotic products market are Integra LifeSciences, Lucina Biosciences, LifeCell International Pvt. Ltd., Orthoflix Medical Inc., and MTF Biologics.

Request for Analysis of COVID-19 Impact on Amniotic Products Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_83262

Amniotic Products Market: Important Trends

Growing Incidences of Burn Injuries to Invite Considerable Growth for Amniotic Products Market

Cases related to burn wounds and injuries have increased extensively over the years. The World Health Organization (WHO) states that nearly 180000 deaths are caused due to burns every year. The statistics by the WHO further highlight that more than 1000000 people are moderately or severely burnt every year. These statistics shed light on the need for treatment to decrease the effect of the wounds. As amniotic products are used for healing such wounds, the demand is expected to increase.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_83262

Implementation of Acts and Numerous Government Initiatives to Accelerate Regenerative Medicine Research brings Considerable Growth Opportunities

Many countries are focusing on boosting research in regenerative medicine. This aspect may have a great impact on the growth of the amniotic products market. Fast-track approvals for novel regenerative medicine products and other factors are also looked upon by introducing various acts and initiatives. Therefore, these factors will bring good growth prospects.

Pre Book Amniotic Products Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_83262&ltype=S

Amniotic Products Market: Noteworthy Regions

The amniotic products market in North America is estimated to observe a dominant stance during the forecast period. The introduction of laws like the 21stCentury Cures Act by the U.S. assures promising growth. Asia Pacific is expected to observe moderate growth during the forecast period.

More Trending Reports by Transparency Market Research:

Interventional Radiology Market According to Transparency Market Researchs latest report on the global Interventional Radiology market for the historical period20172018and forecast period20192027,high incidence of cancer, awareness programs by governments and NGOs, increase in maternal age and late pregnancies are projected to drive the global Interventional Radiology market during the forecast period

Inhalation and Nasal Spray Generic Drugs Market According to the report, the global inhalation and nasal spray generic drugs market was valued atUS$ 27.5 Bnin2018and is anticipated to expand at a CAGR of4.80%from2019to2027

Life Sciences BPO Market Gene therapies, intelligent drug discovery, telemedicine, and the likes are bringing about a change in the life sciences BPO market. Companies in the market for life sciences BPO are innovating through AI and machine learning (ML) for drug discovery.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Go here to see the original:
Amniotic Products Market: Growing incidence of burn injuries to drive the market - BioSpace

Posted in Regenerative Medicine | Comments Off on Amniotic Products Market: Growing incidence of burn injuries to drive the market – BioSpace

What the latest COVID research says about breakthrough cases and transmission : Shots – Health News – NPR

Posted: October 16, 2021 at 2:19 am

Gloria Clemons gives a COVID-19 vaccine to Navy veteran Perry Johnson at the Edward Hines, Jr. VA Hospital in Hines, Ill., in September. Scott Olson/Getty Images hide caption

Gloria Clemons gives a COVID-19 vaccine to Navy veteran Perry Johnson at the Edward Hines, Jr. VA Hospital in Hines, Ill., in September.

Conventional wisdom says that if you're vaccinated and you get a breakthrough infection with the coronavirus, you can transmit that infection to someone else and make that person sick.

But new evidence suggests that even though that may happen on occasion, breakthrough infections might not represent the threat to others that scientists originally thought.

Ross Kedl, an immunologist at the University of Colorado School of Medicine, will point out to anyone who cares to listen that basic immunology suggests the virus of a vaccinated person who gets infected will be different from the virus of an infected unvaccinated person.

That's because vaccinated people have already made antibodies to the coronavirus. Even if those antibodies don't prevent infection, they still "should be coating that virus with antibody and therefore helping prevent excessive downstream transmission," Kedl says. And a virus coated with antibodies won't be as infectious as a virus not coated in antibodies.

In Provincetown, Mass., this summer, a lot of vaccinated people got infected with the coronavirus, leading many to assume that this was an example of vaccinated people with breakthrough infections giving their infection to other vaccinated people.

Kedl isn't convinced.

"In all these cases where you have these big breakthrough infections, there's always unvaccinated people in the room," he says.

In a recent study from Israel of breakthrough infections among health care workers, the researchers report that in "all 37 case patients for whom data were available regarding the source of infection, the suspected source was an unvaccinated person."

It's hard to prove that an infected vaccinated person actually was responsible for transmitting their infection to someone else.

"I have seen no one report actually trying to trace whether or not the people who were vaccinated who got infected are downstream and certainly only could be downstream of another vaccinated person," Kedl says.

There's new laboratory evidence supporting Kedl's supposition. Initially, most vaccine experts predicted that mRNA vaccines like the ones made by Pfizer and Moderna that are injected into someone's arm muscle would generate only the kinds of antibodies that circulate throughout the body.

But that might not be the whole story.

"I think what was the big surprise here is that the mRNA vaccines are going beyond that," says Michal Caspi Tal, until recently an instructor at Stanford University's Institute for Stem Cell Biology and Regenerative Medicine and now a visiting scientist at the Massachusetts Institute of Technology.

What Tal has found is that in addition to the circulating antibodies, there was a surprisingly large amount of antibodies in mucosal membranes in the nose and mouth, two of the primary entry points for the coronavirus.

Immunologist Jennifer Gommerman of the University of Toronto found this as well.

"This is the first example where we can show that a local mucosal immune response is made, even though the person got the vaccine in an intramuscular delivery," Gommerman says.

If there are antibodies in the mucosal membranes, they would likely be coating any virus that got into the nose or throat. So any virus that was exhaled by a sneeze or a cough would likely be less infectious.

Gommerman says that until now, it seemed likely that a vaccine that was delivered directly to the mucosal tissue was the only way to generate antibodies in the nose or throat.

"Obviously a mucosal vaccination would be great too. But at least we're not sitting ducks," Gommerman says. "Otherwise everyone would be getting breakthrough infection."

Now, these studies by Gommerman and Tal have yet to undergo peer review, and some have already suggested that the antibodies they have described may not confer true mucosal immunity.

But there's other evidence that a vaccinated person's breakthrough infection may not transmit efficiently to others.

Marion Pepper, an immunologist at the University of Washington, says a recent study from the Netherlands looked at how well virus from vaccinated people could infect cells in the lab.

Pepper says the answer was not well.

"If you actually isolate virus from people who are getting a secondary infection after being vaccinated, that virus is less good at infecting cells," Pepper says. "It's not known why. Is it covered with an antibody? Maybe. Has it been hit by some other kind of immune mediators, cytokines, things like that? Maybe. Nobody really knows. But the virus does seem to be less viable coming from a vaccinated person."

More studies are emerging that suggest there's something different about the virus coming from a vaccinated person, something that may help prevent transmission.

Whatever it is, the University of Colorado's Kedl says it's one more reason that getting vaccinated is a good idea.

"Because you're going to be even more protected yourself. And you're going to be better off protecting other people."

Kedl says that's what you call a win-win situation.

See the rest here:
What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR

Posted in Regenerative Medicine | Comments Off on What the latest COVID research says about breakthrough cases and transmission : Shots – Health News – NPR

Cell-Based Regenerative Medicine Market Analysis by SWOT, Investment, Future Growth and Major Key Players to 2031 Otterbein 360 – Otterbein 360

Posted: October 16, 2021 at 2:19 am

insightSLICE recently published a study titled Cell-Based Regenerative MedicineMarket Research Report.In this report, analysts have provided a detailed assessment of the Cell-Based Regenerative Medicine market with more than 100 market data tables, pie charts, graphs, and figures

This market study analyzes the market situation, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and barriers to entry, sales channels and the distributors.All statistical and numerical data, which are calculated with the most established tools such as SWOT analysis, are represented using graphs and tables for the best user experience and clear understanding.By using this Cell-Based Regenerative Medicine market report, general market conditions, existing trends and trends in this industry can be discovered.

Request a Free Sample Copy athttps://www.insightslice.com/request-sample/59

Highlights of the study report

COMPETITION ANALYSIS :

The competition model in the Cell-Based Regenerative Medicine market provides detailed information by the competitors.Detailed information includes company profile, company finances, revenue generated, market potential, R&D investments, new market plans, regional presence, strengths and weaknesses of the company. business.company, product versions, product width and width, and application benefits.

Manufacturers Covered By This Report:

Acelity (KCI Concepts), Cook Biotech Inc. Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., and NuVasive, Inc., Medtronic , Stryker Corporation, Integra LifeSciences, and C.R. Bard.

Market segmentation :

The Cell-Based Regenerative Medicine market report has been separated on the basis of distinct categories such as product type, application, end-user, and region.Each segment is assessed on the basis of CAGR, share and growth potential.This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the Cell-Based Regenerative Medicine Market and its growth potential in the years to come.

Request a discount before purchasing this report @https://www.insightslice.com/request-discount/59

Regional analysis:

In addition to segmentation, the report also presents highly structured regional studies.The researchers comprehensive regional analysis highlights key regions and their major countries that account for a significant share of the Cell-Based Regenerative Medicine market revenue.The research helps to understand the market performance in various regions while also mentioning emerging regions which are growing at a significant CAGR.Here are the regions covered by this report

Europe(Germany, France, United Kingdom, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)North America(United States, Canada)Asia-Pacific(China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)Middle East and Africa(Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)Latin America(Brazil, Mexico, Argentina, Colombia, Chile, Peru).

The report answers questions such as:

Table of Contents: Global Cell-Based Regenerative Medicine Market Research Report 2021-2031

Chapter 1: Overview of the Cell-Based Regenerative Medicine MarketChapter 2: Economic Impact of the Cell-Based Regenerative Medicine MarketChapter 3: Competition by ManufacturerChapter 4: Production, Revenue (Value) by Region (2021-2031)Chapter 5: Supply (Production), Consumption, Export , Import by Regions (2021-2031)Chapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Cell-Based Regenerative Medicine Market Analysis by ApplicationChapter 8: Cell-Based Regenerative Medicine Market by Manufacturing Cost AnalysisChapter 9: Chain Industry, Supply Strategy and Downstream BuyersChapter 10: Cell-Based Regenerative Medicine Marketing Strategy Analysis, Distributors / TradersChapter 11: Analysis of effect factors of the Cell-Based Regenerative Medicine marketChapter 12: Forecast of the Cell-Based Regenerative Medicine market (2021-2031)Chapter 13: Appendix

If you have any questions, ask our experts @https://www.insightslice.com/request-customization/59

Contact Information422 Larkfield Ctr # 1001, Santa Rosa,CA 95403-1408, USAinfo@insightslice.com+1 (707) 736 6633

Continue reading here:
Cell-Based Regenerative Medicine Market Analysis by SWOT, Investment, Future Growth and Major Key Players to 2031 Otterbein 360 - Otterbein 360

Posted in Regenerative Medicine | Comments Off on Cell-Based Regenerative Medicine Market Analysis by SWOT, Investment, Future Growth and Major Key Players to 2031 Otterbein 360 – Otterbein 360

Five Coastal Spine Physicians Have Been Reviewed & Approved By NJ Top Docs For 2021 – PR Web

Posted: October 16, 2021 at 2:19 am

Coastal Spine

SCOTCH PLAINS, N.J. (PRWEB) October 15, 2021

NJ Top Docs has reviewed and approved Seth Scholl, DO, Mark A. Testaiuti, MD, Scott Jarmain, MD, Larry Deutsch, MD and Kamaldeep Singh Momi, MD of Coastal Spine for 2021.

Dr. Kam Momi is the founder of Coastal Spine. He has been Chief of the Spine Surgery Department for Jefferson South Jersey Hospitals since 2019. He is a board-certified orthopedic surgeon whose focus is exclusively on the neck and spine.

Dr. Deutsch is a board-certified orthopedic surgeon who has specialized in spine surgery for more than 30 years. He cofounded the Cooper Shriner spine fellowship program and has trained both orthopedic surgeons and neurosurgeons in spine surgery. Dr. Deutsch has been on the cutting edge of innovative procedures, which he has taught in both local and national settings.

Dr. Testaiuti is a board-certified neurosurgeon who specializes in spine care, complex spinal surgery, and minimally invasive spine surgery. He co-founded the Cooper Shriner spine fellowship program and has trained both orthopedic surgeons and neurosurgeons in spine surgery.

Dr. Jarmain is a specialist in physical medicine and rehabilitation, as well as pain management. He focuses on nonsurgical care of spine disorders. He performs spinal injections for diagnostic and therapeutic purposes throughout the entire spine. He also promotes Regenerative Medicine: where a patients own Platelet Rich Plasma, Stem Cells & Concentrated Bone Marrow Aspirate are utilized to treat chronic & acute injuries of joints, tendons, ligaments and the spine.

Dr. Scholl is a specialist in physical medicine and rehabilitation and deals solely with the nonsurgical treatment of neck, back and joint pain. He is the director of electrodiagnostics in which he performs all the pain-less EMGs and supervises the intraoperative monitoring uses during surgery.

Please visit the links below to learn more about these NJ Top Docs:

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:

See the original post:
Five Coastal Spine Physicians Have Been Reviewed & Approved By NJ Top Docs For 2021 - PR Web

Posted in Regenerative Medicine | Comments Off on Five Coastal Spine Physicians Have Been Reviewed & Approved By NJ Top Docs For 2021 – PR Web

CRISPR Therapeutics Announces Transition of Chief Financial Officer – BioSpace

Posted: October 16, 2021 at 2:19 am

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr. Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition.

I'm excited to welcome Brendan to our leadership team. His appointment comes at a time of significant opportunity and growth for CRISPR Therapeutics, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. Brendans business and financial expertise will be important in helping us continue to evolve the Company and realize our mission of transforming the lives of patients with serious diseases.

Dr. Kulkarni added: On behalf of the Board of Directors, shareholders, and our employees, I want to thank Mike for his contributions as CFO and for his dedicated service since joining CRISPR Therapeutics. Mike has been a valuable part of the continued development of the Company, and we wish him all the best in his retirement and look forward to working with him on a smooth transition.

Prior to CRISPR Therapeutics, Mr. Smith was the Chief Financial Officer & Corporate Strategy of Translate Bio, a leading mRNA company that was recently acquired by Sanofi for $3.2B. Mr. Smith is an accomplished executive with more than two decades of experience within high-growth biopharma environments where he made significant contributions in various operations and strategy positions. In these positions, Mr. Smith provided strategic financial leadership relating to long-term growth planning focused on operational efficiencies, building manufacturing and supply capabilities, and evaluation of business development opportunities and commercial planning assessments. Previously, as a Partner at Boston Consulting Group, Mr. Smith led integrated biopharma client engagements that included planning and executing on R&D strategy, operations, business development and deal diligence. Prior to that, Mr. Smith was VP, Head of Business Operations for Worldwide R&D at Pfizer, where he led financial and headcount planning across discovery and development operations. Prior, in his role as Executive Director, Head of Business Strategy and Operations for Biologics Pharmaceutical Sciences at Pfizer, Mr. Smith led manufacturing and financial operations for the companys global biologics process development organization. Mr. Smith received a B.S. in Biochemistry from Worcester Polytechnic Institute and an M.B.A. from Harvard Business School.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides+1-617-315-4493rachel.eides@crisprtx.com

More:
CRISPR Therapeutics Announces Transition of Chief Financial Officer - BioSpace

Posted in Regenerative Medicine | Comments Off on CRISPR Therapeutics Announces Transition of Chief Financial Officer – BioSpace

College Student and Retired Teacher to Thank Stem Cell Donors They’ve Never Met for Saving Their Lives During City of Hope’s 45th Bone Marrow…

Posted: October 16, 2021 at 2:18 am

DUARTE, Calif.--(BUSINESS WIRE)--As a 16-year-old high school sophomore, Julian Castaeda was focused on running track specifically, trying to run a mile in under five minutes. He was also planning to attend two camps that summer that would help him prepare for the rigors of college.

Despite being diagnosed with precursor B cell acute lymphoblastic leukemia at age 10 and receiving chemotherapy on and off for three and a half years, Castaeda had been in remission for two years. He had moved on from that difficult experience.

But in March 2017, Castaeda and his mother, Erica Palacios, again received devastating news the leukemia had returned. Castaeda received chemotherapy for a few months, but the cancer kept proliferating. Castaeda would need a hematopoietic stem cell transplant (more commonly referred to as a bone marrow transplant, or BMT) this time to put his cancer back into remission.

It was heartbreaking. I knew at that point that all my plans for sophomore year would be gone, Castaeda recalled.

But Castaeda was determined to get his life back. This was possible thanks to Johannes Eppler, 27, of Breisach, Germany, who joined the bone marrow registry via DKMS, an international nonprofit that is dedicated to the fight against blood cancers and blood disorders, including the recruitment of bone marrow donors. Castaeda received a bone marrow transplant on Aug. 2, 2017, putting the cancer into remission.

He has a big heart, Palacios said about Eppler. Hes an angel. He saved my son. I am thankful that people are willing to [donate].

Castaeda, who grew up in Bakersfield, California, and was treated by City of Hopes Joseph Rosenthal, M.D., M.H.C.M., the Barron Hilton Chair in Pediatrics, is now 20 years old and a junior at California State University Northridge. He also founded Bags of Love Foundation, a nonprofit that has delivered more than 200 care packages to young cancer patients in treatment and has provided $11,000 in scholarships to survivors.

On Friday, Oct. 15, Castaeda will meet his donor for the first time virtually during City of Hopes BMT Reunion. City of Hope, a pioneer and leader in BMT, has hosted a Celebration of Life for bone marrow, stem cell and cord blood transplant recipients, their families and donors for more than 40 years. The celebration honors children and adult cancer survivors, including those who have received autologous transplants, which use a patients own stem cells, and those who received an allogeneic procedure, which require a bone marrow or stem cell donation from a related or unrelated donor.

What began with a birthday cake and a single candle representing a patients first year free from cancer has grown into an annual extravaganza that draws thousands of cancer survivors, donors and families from around the world, as well as the doctors, nurses and staff who help them through the lifesaving therapy.

Each year, patient-donor meetings are the events emotional highlight. Many recipients, though overwhelmed with curiosity and the need to express their gratitude, can only dream of meeting the stranger who saved their lives. City of Hope is making that dream come true for Castaeda, as well as Dona Garrish, a Fullerton, California resident and retired school teacher. Her donor was Michael Fischer, 35, of Wlkau, Germany.

Garrish, 75, received her transplant on March 22, 2017, after it was delayed several times due to infections and other complications that prevented her from going through with the treatment. Garrish, who was diagnosed with acute myeloid leukemia, felt a strong connection to Fischer from the first time a City of Hope employee told her a German male, whom she had never met, was a perfect match for her. She refers to him as her gift from God and her angel on Earth.

He unknowingly encouraged me to fight harder and not to become discouraged, as someday I wanted to meet him and thank him, she added. Garrish recalled watching two patients meeting their donors at the 2017 BMT Reunion. The reunions were held in front of City of Hope Helford Clinical Research Hospital, where Garrish was recovering from her transplant.

While tethered to her IV pole, Garrish looked down from the hospitals sixth floor and said, Thats what I want to do.

City of Hope nurses, doctors and staff were constantly there supporting me every step of the way, even when I couldnt take a single step, said Garrish, who was treated by City of Hopes Liana Nikolaenko, M.D. The timing was urgent, my battle was rough and long, but I live, breathe and enjoy life today because of City of Hope.

Other event highlights include videos of grateful patients wearing the signature BMT buttons that display the number of years since their transplants, comedy by City of Hope BMT patient Sean Kent and a dance/song performed by BMT nurses, known as the Marrowettes. There will be special guest appearances by a Los Angeles Dodger and Katharina Harf, executive chairwoman of DKMS U.S., to congratulate patients, their donors and the BMT program.

During our annual BMT reunion, we express our most heartfelt thanks to the many selfless individuals who each year donate their bone marrow or stem cells to save a persons life, said Stephen J. Forman, M.D., director of City of Hopes Hematologic Malignancies Research Institute and former chair of its Department of Hematology & Hematopoietic Cell Transplantation. Whether the donor is a patients family member or a person she or he has never met, we are all extremely grateful that these donors took the time to donate and gave someone a second chance at life.

About City of Hopes BMT program

City of Hopes BMT program has performed more than 17,000 transplants, making it one of the largest and most successful programs in the nation. The institution has the largest BMT program in California, performing over 700 transplants annually, and is among the top three hospitals in the nation in terms of total transplants performed.

Over the years, City of Hope has also helped pioneer several BMT innovations. In addition to being one of the first institutions to perform BMTs in older adults, it was one of the first programs to show that BMTs could be safely performed for patients with HIV. City of Hope has had growing success with nonrelated matched donors and, most recently, half matched family donors.

City of Hopes BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.

City of Hope was also one of the first programs to develop a treatment for prevention of cytomegalovirus (CMV), a common and potentially deadly infection after transplant, which has nearly eliminated the threat of CMV for BMT patients. The institution successfully conducted clinical trials of a CMV vaccine developed at City of Hope. As a pioneer in the development of CAR T cells to treat cancer, City of Hope is also testing how this form of cancer immunotherapy can help patients have a more successful transplant.

In addition, Be The Match at City of Hope last year added more than 13,000 new volunteers willing to save a life when they match a patient who needs a bone marrow transplant. In total, nearly 300,000 potential donors have signed up via City of Hope, motivated by a patient at the cancer center. Be The Match encourages healthy individuals between the ages of 18 and 40 to take the first step of registering by texting COHSAVES to 61474. To learn more about the donation process, visit Be The Match at City of Hopes website.

The public can register to view the event here.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. Translational Genomics Research Institute (TGen) became a part of City of Hope in 2016. AccessHope, a subsidiary launched in 2019, serves employers and their health care partners by providing access to NCI-designated cancer center expertise. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Read more:
College Student and Retired Teacher to Thank Stem Cell Donors They've Never Met for Saving Their Lives During City of Hope's 45th Bone Marrow...

Posted in Stem Cell Videos | Comments Off on College Student and Retired Teacher to Thank Stem Cell Donors They’ve Never Met for Saving Their Lives During City of Hope’s 45th Bone Marrow…

The Mystery of Smell – Harvard Magazine

Posted: October 16, 2021 at 2:18 am

In the early weeks of the pandemic, as scientists and physicians scrambled to find the edges of this new, dangerous diseasehow it spread from person to person, how it behaved inside the human body, and how they might be able to stop itone emerging symptom sent a jolt of recognition through Sandeep Robert Datta: the sudden disappearance of many patients ability to smell.

A professor of neurobiology, Datta studies olfaction: what happens between nose and brain as sensory neurons pick up a smell and the signal makes its way to the olfactory cortex, where the information is transformed into something we recognize as coffee, or roses, or dirty socks. But the news that smell loss could be a symptom of COVID-19 jolted him on another level tooas a graduate student in his early 20s, Datta had briefly lost his own sense of smell and taste. For him, it was a side effect of chemotherapy. It was pretty horrible, he recalls. Emotionally, he felt disoriented and disconnected, strangely set adrift. Physically, it became almost impossible to eat: I just found nothing palatable at all. What finally worked was fried egg and cheese sandwicheseven without taste or smell, the saltiness was perceptible, and the texture made them easier to swallow. For a while, this was the only thing he ate. I had a cholesterol of 300, he says, but it got me through. And after a couple of months, his smell and taste recovered. So, I have some sense, he says, of what its been like for people with this virus.

As a scientist, though, he also knew something else: there werent going to be many answers for those patients questions, at least not yet. Despite years of research in labs like his, much about olfaction remains, essentially, a mystery. So much is still just open science, says Datta, who last year led a study that uncovered how COVID-19 seems to disrupt the sense of smell. Right now, theres a lot of intense interest in smell, he says, from physicians and from the many millions of patients whove had their sense of smell affected. And it has really highlighted, collectively, how little we know about all aspects of our sense of smell.

Researchers do have a grasp of the rudiments: that specific odor molecules bind to matching receptor proteins in the noses sensory neurons like keys in a lock, and that when each lock is opened, an electrical signal travels to the brains olfactory bulb, which in turn relays the message to other parts of the brain, where it is processed furtherthe piriform cortex, which identifies smell; the thalamus, which acts as a relay station; the orbitofrontal cortex, which is involved in taste. But even this knowledge is somewhat recent. The landmark genetic study identifying hundreds of different olfactory sensors in the nasal neurons was published only in 1991. That breakthrough won the Nobel Prize for its authors, biologists Linda Buck and Richard Axel, and opened the door to a whole new universe of research. Still, 30 years later, much of the olfactory system remains unmapped.

One reason for the persistence of this mystery is sociological, Datta says: humans are visual creatures. Losing the sense of sight is a psychologically devastating change that substantially impairs peoples ability to navigate everyday existence. Fully one-third of the human brain is devoted to processing visual information. No surprise, then, he says, that from the beginning, modern neuroscience focused most intensely on deciphering sight (and, then, hearing). We have tended to think of olfaction as a kind of bonus sense, an aesthetic sense, Datta says, an accessory to these more essential sensory processes. That comes through in the paucity of language to describe it. Vision and hearing abound with adjectives, but humans vocabulary for what something smells like is fuzzy and fragmentary and highly variable. This is a huge hurdle for science: its extraordinarily difficult for people to convey their olfactory perceptions in a way that is comprehensible to researchers.

Scientists have no such command over the levers of smell. I mean, what is smell, precisely? Datta asks. If I take a sniff of my morning coffee, thats not actually a thing. Its 800 separate volatile chemicals.

Then there is the problem of smell itself. Scientists have a robust understanding about the dynamic components of a visual object or a soundattributes like shape, color, light intensity, pitch, volume, frequency, directionand they can vary these elements with precision during laboratory experiments to stimulate the brain and study how, for instance, a brighter color or a louder sound is processed. But scientists have no such command over the levers of smell. I mean, what is smell, precisely? Datta asks. If I take a sniff of my morning coffee, thats not actually a thing. Or at least, not one single thing: Its 800 separate volatile chemicals that are coming off into the headspace above the cup, all of which exist at different concentrations, which my nose detects and my brain synthesizes into a unitary percept of coffee.

Its not clear, Datta says, how these chemicals interact with each other, or with the nose; its also not clear which chemicals mean the most to the olfactory system, and which it ignores, or under what circumstances it registers any given chemical as pleasant or unpleasant. Sulfur, the rotten-egg smell so noxious to humans it is added to odorless natural gas as a safety warning for gas leaks, is also an essential component of garlic, onions, and certain perfumes; the purified compound MMB, which is what makes cat urine smell intolerable, is also sold, at low concentrations, as a food additive to enhance flavor. We dont know the axes that odor chemistry is organized along, or how they matter to the brain, Datta says. Changing as little as one odor molecule can dramatically alter olfactory perception in ways that we, as scientists, simply do not understand right now.

And yet, olfactory research holds a tantalizing promise: by unraveling the intricacies of smell, neuroscientists might be able to crack open deeper mysteries of how the brain itself works. Thats partly because smell is thought to be the earliest evolved sense in mammals. The olfactory bulb sits near the bottom of the brain, layers below the more recently developed folds of the neocortex. Its neural circuits are ancient, andunlike vision and hearing, whose signals must trace a longer pathintimately connected to other primordial brain centers: the hippocampus, where memories are stored, and the amygdala, responsible for processing many aspects of the emotional world, including fear and threats. (The amygdala is thought to play a major role in anxiety and post-traumatic stress disorders.)

Odors have the power to trigger intense memories and emotions, and can profoundly influence mental healthas many COVID patients attest, people who suddenly lose the ability to smell often struggle with depression and emotional wellbeing. Loss of smell is linked to increased mortality risk and considered an early warning signal for neural illnesses like Alzheimers, Parkinsons disease, and schizophrenia. Children with autism have a heightened sensitivity to smell and a different sniff response from neurotypical children. This kind of intimacy between sense of smell and these parts of the brain that are fundamental to our human experience is super intriguing, Datta says. The simplicity of the circuits, and the directness of their connections to places like the hippocampus or the amygdala, offer a potential window into how our brains might sense information and transform it into a memory or an emotion, and then ultimately a behavior.

That same curiosity is also what attracted Venkatesh Murthy, Erikson life sciences professor of molecular and cellular biology and Finnegan Family Director of the Harvard Center for Brain Science. For Murthy, too, olfaction seemed a useful way in to larger questions about the brain. The reasoning was partly practical. In neuroscience, one common research subject is mice, whose neural circuitry approximates humans in important ways; and for mice, smell is dominant, the most profound sense they have for navigating the world. (In mice, it is smell that takes up one-third of the brain.) Researchers can train rodents to respond to specific odors remarkably easily. We think of animal training as difficult, Murthy says. For people who train dogs or horses, for instance, its very laborious. You cannot just tell them the rules, because they cant understand you, and so you have to reinforce the right behavior for each command over and over. But communicating through smell is remarkably smooth. Essentially, scientists can tell mice the rules. Its such an intuitive sense for them, he says, that we are able to train animals to do very complicatedor at least, what we think are very complicatedtasks. And they are able to do them beautifully.

Some of those tasks explore the connection between olfaction and memory: how animals use smells to store memories, and how that process might alter neural activity for those smells. (Murthy has found that it takes mice only a few minutes to make the connection between an odor and a specific corresponding reward, that a whiff of vanilla, for instance, means a sip of water, or a chocolate chip.)

Other experiments, which Murthy calls the olfactory cocktail party, use mice to help decipher the brains strategies for sorting through the cacophony of messages arriving from the tens of thousands of neurons in the nose. Lets say youre in a room where somebody is brewing a fresh pot of coffee and they also put on some really nice perfume, Murthy says. And lets say there are also flowering plants in the background, and food on the stove. How does a person recognize any one smell, when its embedded in so much clutter and chaos? Especially given that each odor is not a single chemical, but numerous ones? This is a long-term question, Murthy says, but mice offer clues: in a mixture of up to 16 smells, they are consistently able to identify whether a particular smellsay, bananais present. One hypothesis is that animals somehow train their sense of smell; after all, sommeliers and coffee tasters manage a similar feat. Or the explanation could be more purely biologicalin mice, the synapses of the olfactory cortex appear more plastic than in the visual cortex, Murthy says. So maybe the brain does have this ability to rewire connections and make associations.

Recently, Murthy has been investigating a new mystery: how animals follow scent trails. Its a deeper question than it seems. You might think, how hard can that be? Murthy says. But actually, its not so easy. I mean, close your eyes and imagine that you smell something. What do you do next? Wheres the next part of the trail? Its completely unobvious. To approach this problem Murthy uses an inkjet printer to print rose-scented trailssometimes straight, sometimes curvedonto long strips of paper, which he fastens on to a contraption that acts as a treadmill for mice. Four separate video cameras capture every move as they sniff their way down the page, and AI software converts the videos into data. The next step, Murthy says, is to use electrodes to start understanding which parts of the brain are involved.

In the meantime, hes taken a potentially elucidating sidestep: running the treadmill experiment with carpenter ants and pheromone trails. Its yielded some intriguing results, he says. On his laptop, he pulls up a brief clip of one of the ants, up close and in black and white. It proceeds slowly, losing its way, correcting the mistake, turning around, proceeding again. Ants do not have nosestheir sensory neurons are located in their antennae, and in the video, the antennae sweep from across the trail, sometimes opening wide like windshield wipers, sometimes bending and stretching like an extra pair of legs. We were shocked to find they were so active with their antennae, Murthy says. Ants are too small to measure their neural activity, so we can only watch this behavior, we cant look inside yet, he says. Turnng back to the video, he watches the mystery unfold in front of him, while the ant on the screen keeps moving slowly forward, smelling its way back to the trail, not knowing exactly where its headed.

In his own lab, Datta is trying to answer a similar question: how smells help the brain build models of the world. Those models allow animals (and humans) to make predictions about their surroundings and then decisions about what to dowhether to turn to the right or the left, whether to run, or eat, or fight, or mate. One study Datta has been working on probes a phenomenon called adaptation. You know how, when you first step into someones kitchen, you smell all the smells of the cooking food? he asks. But then, over time, it dissipates and you stop noticing all the smells. Thats adaptation, the olfactory systems way of allowing the brain to focus on whats new or important, rather than whats simply there. So, if somethings burning, youll smell it, as opposed to having your senses overwhelmed. Datta wanted to learn how that process works, specifically in the olfactory neurons in the nose. Traditionally, people have thought this process occurs in the brain, but weve been asking whether it actually happens before information even gets to the brain. As part of the study, he sequenced cells in mices olfactory epithelium (the thin tissue of neurons and surrounding cells lining the upper nasal cavity) to determine what RNA each cell expressed.

That was the project Datta was working on when the pandemic struck and everything abruptly shut down. Marooned from his lab and reading the proliferating accounts of COVID patients losing their sense of smell, he realized that the sequencing data hed amassedand similar stockpiles in the hands of other smell researchers he knew around the globemight point to an explanation. We were lucky that we had all this stuff on our hard drives, he says. A few months later, in July 2020, Datta and 24 coauthors published their findings. Early analyses had shown that the virus attaches to its host using the ACE-2 receptor protein. But that protein is not expressed by the olfactory neurons; instead, its expressed by cells surrounding the neuronsstem cells, which allow damaged neurons to regrow, and sustentacular cells, which provide physical and metabolic support. The researchers theorized it was those surrounding cells the virus was infecting.

This idea might also explain why some patients recovered their smell quickly, and some patients not at all. If the infected cells were so damaged that the neuron also died, it would take months for the neuron to regrow. And in some cases, perhaps the viral destruction in the epithelium, especially to the stem cells, was so complete that the neurons would never be able to regrow, and sense of smell would never return.

Before COVID, Datta says, It was hard to get many peoplesome scientists includedto pay attention to smell as a legitimate wedge that one might use to understand the brain. And I think thats really changed now. For researchers like him and Murthy, the fresh urgency directed at their field is an unfamiliar feeling, but a galvanizing one. Im excited to begin to think more about the underlying problem of smell itself, Datta says. Murthy foresees a renaissance in olfaction research. Lately hes been contemplating how breathing and smelling might intertwine neurologically.

Much of the new primacy felt by researchers like Datta and Murthy has to do with the increasingly acute, COVID-driven need for therapies. Right now, we have no clinically validated treatments for the loss of smell as a result of a virus or trauma, Datta says. Some studies suggest modest efficacy in the practice of smell training, in which patients try to recover their sense by regularly breathing in specific odors, But for the most part, Datta says, I dont have a drug that I can give you that will fix your broken olfactory system. We dont even know for sure what level those interventions should be made at. If you lose your sense of smell because your nose has been damaged by the coronavirus, is it enough if I simply fix your nose? Do I also have to fix the brain? We just dont know.

Eric Holbrook began hearing about the COVID-related smell loss a few weeks before it started showing up in his clinic. Director of the rhinology division at Massachusetts Eye and Ear and associate professor at Harvard Medical School, Holbrook had seen bad colds and other viruses occasionally knock out patients olfactory systems for long periods, but hed never seen the sheer number of smell-loss patients that COVID-19 produced: whole families, friend circles, half the floor of a single dorm. And those with long-term loss skewed youngerrather than in their 30s or 40s, COVID patients were often college-aged, or not much beyond, Holbrook recalls. I saw one kid who was nine.

The lack of proven, reliable treatments for smell loss can drive patients to desperation, Holbrook says. It puts physicians in the position of wanting to try everything. And that can be dangerous.

About 85 percent of COVID patients with mild infections seem to suffer loss of taste and smellfor many, it is the earliest symptom, or the only one. And although most regain their ability to smell within three or so weeks, for as many as 35 percent, the loss lasts longer. Those conversations with patients can be hard, Holbrook says. There is usually not much he can do. Smell training sometimes works: a months-long regimen of inhaling smells twice a day in an effort to reactivate the neurons. But the lack of proven, reliable treatments can drive patients to desperation, Holbrook says. You wouldnt believe the number of people who ask me about so-called therapiesmedicines, devices, surgeries abroadthat have no proof, or even very much scientific rationale. It puts physicians in the position of wanting to try everything. And that can be dangerous. It can also lead to false hope.

Like Datta and Murthy, Holbrook is surrounded by unknowns. Although he has some ideas, he is not sure what to make of the numerous reports from COVID patients who say they are incapable of detecting only certain odorsbathroom smells especially. And although he knows its usually a good sign when patients progress from an absent sense of smell to a distorted onein which coffee might smell like sewage, or food like cigaretteshe cannot yet explain exactly why. Doctors have long recognized it in trauma patients as an indication that the olfactory system is working to heal itself, and the neurons perhaps mis-wiring as they grow back, but the mechanism remains murky.

Olfactory sensory neurons are a rare part of the human nervous system capable of regeneration. Thats what first gripped Holbrook, as a medical student sitting in a classroom listening to a lecture on neuroanatomy. After neurons die, they can come back. That was completely fascinating to me, he says. It still is. For the past several years, he has been collaborating on possible therapies for smell loss. One, led by researchers at Tufts University, involves stimulating the systems stem cells. In a lot of cases, after damage has occurred, he says, those stem cells are sitting there, very quiet. And it looks like there are ways we can tell them to start dividing and making neurons again.

Another project, which Holbrook sometimes calls a cochlear implant for the nose, would use electrodes to stimulate the nerves in the olfactory bulb. Its still a distant dream, but in 2018, he and several collaborators conducted a small experimenta proof of concept placing electrodes inside the nasal cavities of five patients with intact senses of smell, very close to the olfactory bulb. After the researchers administered an electric current, three patients described experiencing sensations of antiseptic, sour, and fruity aromas. One said it was onion-like, but not an onion, Holbrook says. The results were encouraging enough to warrant more research. Neurosurgeon Mark Richardson, who founded the Brain Modulation Lab at MGH, is pushing that effort forward.

In the paper Holbrook and his colleagues published after their 2018 experiment, they estimated that five percent of the population suffers from total smell loss. After COVID-19, that number seems almost certain to rise. The implications of this virus are huge, Holbrook says. Some of his patients who lost their sense of smell early in the pandemic still have not regained it. Theres a big, significant number of people who are going to be potentially without smell for the rest of their lives, he says. There is so much work that still needs to be done.

Read the original:
The Mystery of Smell - Harvard Magazine

Posted in Stem Cell Videos | Comments Off on The Mystery of Smell – Harvard Magazine

3D Printing Applications in the Fight Against Breast Cancer – 3Dnatives

Posted: October 16, 2021 at 2:18 am

According to the World Health Organization (WHO), by the end of 2020, 7.8 million women alive had been diagnosed with breast cancer in the past 5 years, making it the worlds most prevalent cancer as well as one of the leading cause of cancers death in women worldwide. There are also men who suffer from the cancer, with the CDC finding that 1 in 100 breast cancer patients is male. Out of these women in particular, 40% require a mastectomy, the partial or total removal of a breast, for recovery. However, only about 20% of these women choose breast reconstruction (recreating the breasts after removal), even though it is often recommended to patients. In order to support the current, past and future breast cancer suffers, October was designated as Breast Cancer Awareness Month. In honor of that, we decided to take a look at the different ways that 3D printing can be used to help combat breast cancer, including through reconstruction. You can find our choices, in no particular order, below!

One creative way that 3D printing is being used is at the University of Texas MD Anderson Cancer Center. When patients are told about their tumors, it can be hard to understand what they really resemble since mammogram images only offer a two-dimensional view. This in turn can make them confused about which treatment to choose. MD Anderson has found a solution to this with 3D printed replicas of breasts and the tumors inside. Using 3D printing, radiologists Elsa Arribas and Lumarie Santiago started to make 3D-printed personalized breast models to more accurately illustrate the tumors. This has helped both doctors and patients at the center to understand their treatment options, it can also be used as a 3D guide during surgery, resulting in more efficient operations with fewer complications.

Using 3D printing to better illustrate breast cancer tumors (photo credits: MD Anderson)

Hyperthemia is a cancer treatment in which body tissue is heated to a high temperature that will kill and damage cancer cells while leaving normal tissue intact. Microwave breast hyperthemia in particular is one potential cancer treatment in which breast temperature is raised using electromagnetic (EM) radiation. This particular treatment can be difficult as it is often done using bulky, rigid systems that are uncomfortable for the patient. However, Yusuku Makai, Sizian Li and Minyoung Suh have potentially found a way to improve it using 3D printing. In their study 3D-printed thermoplastic polyurethane for wearable breast hyperthermia, the researchers posit that instead of using the traditional systems, 3D printed wearable antennas would be superior. They ultimately found that the 3D printed antennas could be used and not only provided more comfort to their patients but allowed for adjusted levels of exposure, however there were still limitations that needed to be addressed.

The design of the antennas (photo credits: Yusuku Makai, Sizian Li and Minyoung Suh)

With many of the traditional breast reconstruction procedures relying on a limited supply of human cadavers or animal tissue, CollPlants innovative 3D bioprinting approach removes this supply constraint, allowing for wider reconstruction access for more patients. Earlier this year, CollPlant and 3D Systems entered a co-development agreement to co-produce a 3D bioprinted soft tissue matrix product that is able to promote cell infiltration and proliferation by using bioink formulations based on rhCollagen. This tissue regeneration minimizes the risk of adverse immune response. Due to its plant-based origin, the rhCollagen also offers superior safety while meeting the mechanical requirements for implant procedures.

Photo Credits: 3D Systems

A team of scientists from several medical institutions in China, joined forces to conduct a study on localized chemotherapy breast cancer treatment. Traditional chemotherapy is delivered in massive doses, resulting in toxic side effects including hair loss, anemia, and nausea. Using 3D printing technology, the team of researchers designed a prosthesis containing the drugs paclitaxel (PTX) and doxorubicin (DOX) in order to prevent the recurrence of malignant tumors and metastasis following breast cancer-related surgery. The drug release showed that the 3D-printed prosthesis containing PTX and DOX microspheres was capable of releasing the drugs continuously for over 3 weeks, wherein suppressing a cancer recurrence threshold, and with significantly reduced side-effects. While the study was conducted on mice, this study revealed promising results for future development of breast cancer treatments in humans.

Photo Credits: Drew Hays/Unsplash

Since its founding in 2017 in Lille, the startup Lattice Medical has raised 2.3 million. Funds that have enabled it to develop an innovative application for breast reconstruction. The company has developed a bioprosthesis called MATTISSE, to offer an alternative to silicone prostheses, which require surgery every 10 years. Made of an absorbable material, the MATTISSE bioprosthesis is perfectly adapted to the patients morphology thanks to 3D printing. And unlike silicone prostheses, since it is resorbable, only one operation is required. To design the bioprostheses, the young company is inspired by the properties of Calais lace and uses a 3D printed dome that serves as a guide for cell growth. And thats one of the main advantages of MATTISSE bioprostheses they allow for natural reconstruction because it regenerates the patients own fatty tissue. When it comes to the process used to produce the prostheses, Lattice Medical uses FDM technology.

Photo Credits: Lattice Medical

Founded in Lyon in January 2020, Healshape is a biomedical startup specialized in breast reconstruction and augmentation via bioprinting. Similar to Lattice Medical, it offers a fully customized bioprosthesis bioprinted from an ink that facilitates the regeneration of each womans tissue. The prosthesis is resorbable, designed from natural biomimetic materials. Once implanted, the doctor can inject the patients own cells by performing lipofilling. Thus, only one operation is necessary. These cells will then adopt the shape of the bioprosthesis and will be able to reconstruct breast tissue. After a few months of work, the prosthesis will be able to resorb itself, leaving only the patients own cells, which should then be able to recover their breast.

The New Zealand company myReflection relies on 3D scanning to develop custom-made breast prostheses. The principle is simple: each patient goes to one of the brands centers and one of the consultants will perform a scan of the breast using a portable 3D scanner. After working on the 3D model, the teams 3D print a prototype shell in PLA to check the shape, fit and size of the prosthesis. If the patient agrees, then manufacturing of the prosthesis can begin (it is not 3D printed). For the moment, myReflection only delivers in New Zealand; count 613 New Zealand dollars (about 370 euros) for the scanning and testing phase and 3 prostheses.

Photo Credits: myReflection

A research group at the University of Girona succeeded in using 3D printing to isolate the cells that cause breast cancer in women. Specifically, they made tiny 3D matrices, called scaffolds, that reproduced the tissues and fibers of the human body. With the help of BCN3D Cura software and the Barcelona manufacturers Sigma 3D printer, they tested various parameters to create the most optimal models for the research. They made 10 copies of each configuration in order to see which geometry best separated the stem cells, which are the ones that cause relapses. By successfully isolating the stem cells of this subtype of cancer, the researchers will be able to study them better to find the biomarkers responsible for the tumors and be able to target them with drugs.

Photo Credits: University of Girona

Together with the Leipzig-based company BellaSeno, Fraunhofer IPT is working on the development of an automated production system that will in future manufacture breast implants from autologous tissue with a polymer structure. In the project, the companies are combining their expertise in 3D printing as well as knowledge in the fields of mechanics, electronics, measurement technology and software. The new method is expected to give hope to many women because conventional implants often provoke a defensive reaction from the body and thus pose an additional health risk to patients. In the case of BellaSenos 3D-printed polycaprolactone implants, the implanted material is said to be completely degraded by the body within two years and the breast will once again consist of the bodys own cells. Thanks to the production facility, it should also be possible to manufacture the implants more efficiently and at a lower cost, which should enable more women to have surgery. However, it will be several years before the implants are approved. The two companies expect to have a first industrial prototype of the plant within the next few years.

Photo Credits: Fraunhofer

Thanks to 3D-printed breast templates, doctors can now better prepare for tumor removal surgery. Behind the project is a research team at Asan Medical Center led by Professor Ahn Sei-hyun, Associate Professor Ko Beom-seok and Assistant Professor Kim Nam-kug. With the help of the template, they say, patients breasts can be replicated using 3D printing and used by doctors for surgery. The whole thing works like this: first, the breast and tumor are modeled. Then, the shape of the tumor is projected vertically on the surface and the model of the breast is printed using a 3D printer. After the patient is placed under anesthesia on the day of surgery, breast template 3D breast guide is placed over the breast with the tumor, allowing the surgical site to be accurately marked. Associate Professor Ko Beom-seok explains the following, Breast cancer surgery using the 3D breast template ensures the exact surgical resection margin, preserving the breast as much as possible by reducing reoperation and recurrence rates and achieving an overall improved cosmetic result.

Photo Credits: Asan Medical Center

Supported by the European Commission and Eureka, a European R&D network, new breast implants will be developed over the next few years using 3D printing. The project is led by Korean biotech startup Plcoskin. Yonsei University and LipoCoat, a Dutch medical device manufacturer, are also expected to contribute their expertise to product development. The goal is to jointly develop a biodegradable PCL-based breast implant. Consequently, the implants will be 3D printed with PCL and previously coated with PCL collagen and lipid films using LipoCoats patented biocoating technology. This method is expected to reduce the infection rate of implants and result in less discomfort for patients after surgery. The project will be subsidized to the tune of $1.7 million over the next few years.

One major application of 3D printing is in the creation of implants for breast cancer patients

What do you think of the applications for 3D printing in the fight against breast cancer? Let us know in a comment below or on our Linkedin, FacebookandTwitter pages! Dont forget to sign up for our free weekly Newsletter here, the latest 3D printing news straight to your inbox! You can also find all our videos on our YouTube channel.

Read more here:
3D Printing Applications in the Fight Against Breast Cancer - 3Dnatives

Posted in Stem Cell Videos | Comments Off on 3D Printing Applications in the Fight Against Breast Cancer – 3Dnatives

C. Oregonians react to OSU study that says sunscreen with zinc loses effectiveness, becomes toxic – KTVZ

Posted: October 16, 2021 at 2:17 am

BEND, Ore. (KTVZ) --Sunscreen that includes zinc oxide, a common ingredient, has been found to lose much of its effectiveness and becomes toxic after two hours of exposure to ultraviolet radiation, according to a study that included Oregon State University scientists.

The OSU study was meant to question how stable, safe, and effective are sunscreen ingredients in combination rather than as individual compounds.

It also looked into the safety of any chemical products that result from reactions caused by exposure to sunlight.

Diana Stevens, a Bend resident, said Thursday she has never liked applying sunscreen on herself or her children. Shes always questioned its ingredients and how safe it is to wear.

Ive tried really hard to find sunscreen that is not toxic, mainly for the health of my children and myself, and its hard to find one, Stevens said.

Instead, she chooses to find shady areas and wear protective clothing when going outdoors.

It actually feels safer not to have the chemicals around my face and mouth, Stevens said.

What the public thinks about sunscreen safety has caused manufacturers who often have on limited data to use lots of some ingredients while limiting others. For example, oxybenzone has effectively been discontinued because of concerns that it harms coral reefs.

The study of measuring toxicity in sunscreen involved using zebrafish, which share a similarity to humans at the molecular genetics and cellular levels, meaning many zebrafish studies are relevant to people.

Chris Martindale, who was out enjoying the Bend Whitewater Park Thursday afternoon, has become conscious of the sunscreen products, and suggests others do the same.

When it comes to the sunscreen products that we use, I would probably just take a second look at what youre putting on your body -- how it affects you, how it affects the environment around you," Martindale said. "If it's worth paying the extra $3 or $4 for a sunscreen that is going to do good in the long term, thats probably the best route to take.

The researchers exposed a number of sunscreen mixtures to ultraviolet radiation for two hours to look into what sunlight did to the compounds in the mixtures and their UV-protective capabilities.

The zinc-oxide-induced mixtures caused significant increases in defects to the zebrafish used to test toxicity. OSU faculty suggest zinc oxide particles are leading to degradants whose introduction to aquatic ecosystems is environmentally hazardous.

Excerpt from:
C. Oregonians react to OSU study that says sunscreen with zinc loses effectiveness, becomes toxic - KTVZ

Posted in Molecular Genetics | Comments Off on C. Oregonians react to OSU study that says sunscreen with zinc loses effectiveness, becomes toxic – KTVZ

Page 634«..1020..633634635636..640650..»